Full-Time
Posted on 10/31/2025
Computational platform for drug discovery
No salary listed
Germany + 1 more
More locations: France
Remote
Schrödinger provides a computational platform for drug discovery used by biopharmaceutical companies, academic institutions, and government laboratories around the world. The core offering is an integrated software suite for molecular modeling, simulations, and analytics, which clients access through software licensing or collaborative research agreements, and may also participate in wholly-owned or collaborative drug-discovery programs. The company differentiates itself with a long history since 1990 and a global footprint, combining a full end-to-end platform with direct drug-discovery partnerships and extensive services. Its goal is to advance science and talent by strengthening its platform and helping partners discover and develop new medicines using computational methods and collaborative programs.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
New York City, New York
Founded
1990
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
401(k) Retirement Plan
Flexible Work Hours
Remote Work Options
Paid Vacation
Parental Leave
Schrödinger, a computational drug discovery and AI company, reported full-year 2025 revenue of $255.9 million with a narrowed net loss of $103.3 million. Despite positive financials, the stock has underperformed, trading at $12.06 per share. The company's share price shows mixed returns: 13.67% over 30 days and 32.93% year-to-date, whilst longer-term investors face losses despite 45.94% one-year and 82.66% five-year returns. Analysts suggest the stock trades at a significant discount to its estimated fair value of $43.20 per share, representing potential 72.1% upside. This valuation assumes strong recurring software revenue, robust margins and successful drug pipeline development. However, risks remain if clinical programmes fail or operating losses persist longer than expected.
Schrödinger reported 2025 revenue of $256 million, up 23% year-over-year, with software revenue of $199.5 million and total annual contract value of approximately $198.5 million. The company narrowed its net loss to $103 million from $187 million in 2024 and ended the year with $402 million in cash. The company is accelerating a shift from on-premise to hosted, cloud contracts, with 23% hosted in 2025 and targeting roughly 75% by 2028. Management noted this transition will materially affect reported revenue timing and margins, with approximately $2–3 million revenue impact per 1% increase in hosted mix. Schrödinger highlighted its therapeutics portfolio with potential milestones up to $5 billion and upcoming clinical readouts, including WEE1/Myt1 Phase I data expected in Q2. The company is also exploring agentic AI integration with Anthropic.
Schrodinger Inc reported total revenue of $256 million for 2025, marking 23% growth, with software revenue at $199.5 million and drug discovery revenue at $56.4 million. The company maintains a cash position of $402 million. However, the company's transition to a hosted model impacted margins, with software gross margin declining to 74% from 80% in 2024. Net loss narrowed to $103 million from $187 million the previous year. Annual contract value grew 4% to $198.5 million, whilst net dollar retention fell to 100% from over 110% previously, reflecting challenging pharma and biotech market conditions. For 2026, Schrodinger guides annual contract value between $218 million and $228 million, representing 10% to 15% growth, with drug discovery revenue expected between $55 million and $65 million.
NEW YORK - (BUSINESS WIRE) - Schrödinger, Inc. (Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hematology Association Annual Congress, taking place June 12 - 15, 2025, in Milan, Italy.
Schrödinger launched its first company-wide Volunteer Month, during which every office globally participated in local community service activities.